Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of ZEB1-regulated gene expression changes in HCC827 human lung adenocarcinoma cells

ABSTRACT: We performed next-generation RNA sequencing for HCC827 human lung adenocarcinoma cells that are stably transfected with pcDNA3.1-ZEB1 or an empty pcDNA3.1 vector plasmid, in triplicate for each of the two HCC827 cell transfectants. The goal of this experiment is to identify putative downstream mediators of ZEB1 in human lung cancer cells. By successfully acquiring about 25 million reads for each sample, we identified more than 1,700 transcripts that are significantly regulated by ZEB1 (increased or decreased by ZEB1; p < 0.05). Among these genes, 87 of them are predicted direct targets for microRNA-200c, a well-established transcription target of ZEB1. Our results will be useful for further identification of genes that mediate the biological functions of ZEB1 in human lung cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE81167 | GEO | 2016/07/12

SECONDARY ACCESSION(S): PRJNA320768

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression of HCC827 and HCC827-TET2-KO cell line [HCC827_TET2_KO_RNA]

Project description:To investigate the influence of TET2 knock-down in lung cancer cell line, We performed gene expression profiling analysis using data obtained from RNA-seq of HCC827 cell line and HCC827-TET2-KO cell line.

2024-03-13 | GSE222829 | GEO

Distribution of genomic 5hmC marks in HCC827 and HCC827-TET2-KO cell line [HCC827_TET2_KO_5hmC]

Project description:To investigate the influence of TET2 knock-down in lung cancer cell line, We performed 5hmC landscape analysis using data obtained from 5hmC-seq of HCC827 cell line and HCC827-TET2-KO cell line.

2024-03-13 | GSE222827 | GEO

Gene expression of HCC827 and HCC827-OR cell line [HCC827OR_RNA]

Project description:To investigate the abnormal gene expression in Osimertinib Resistance lung cancer cell line, We performed gene expression profiling analysis using data obtained from RNA-seq of HCC827 cell line and HCC827OR cell line.

2024-03-13 | GSE223006 | GEO

Analysis of open chromatin structures in HCC827 CBX5 knockdown cells by ATAC seq analysis .

Project description:Briefly, Human lung cancer HCC827 cells were stably expressing either CBX5 shRNAs or control shRNA were analysed for open chromatin structures using ATAC seq Analysis.

2024-02-18 | GSE167071 | GEO

Inhibition of ZEB1 expression induces redifferentiation of adult human β cells expanded in vitro

Project description:In-vitro expansion of functional adult human β-cells is an attractive approach for generating insulin-producing cells for transplantation. However, human islet cell expansion in culture results in loss of β-cell phenotype and epithelial-mesenchymal transition (EMT). This process activates expression of ZEB1 and ZEB2, two members of the zinc-finger homeobox family of E-cadherin repressors, which play key roles in EMT. Downregulation of ZEB1 using shRNA in expanded β-cell-derived (BCD) cells induced mesenchymal-epithelial transition (MET), β-cell gene expression, and proliferation attenuation. In addition, inhibition of ZEB1 expression potentiated redifferentiation induced by a combination of soluble factors, as judged by an improved response to glucose stimulation and a 3-fold increase in the fraction of C-peptide-positive cells to 60% of BCD cells. Furthermore, ZEB1 shRNA led to increased insulin secretion in cells transplanted in vivo. Our findings suggest that the effects of ZEB1 inhibition are mediated by attenuation of the miR-200c target genes SOX6 and SOX2. These findings, which were reproducible in cells derived from multiple human donors, emphasize the key role of ZEB1 in EMT in cultured BCD cells and support the value of ZEB1 inhibition for BCD cell redifferentiation and generation of functional human β-like cells for cell therapy of diabetes.

2015-07-27 | GSE69658 | GEO

Mutational analysis of HCC827 and HCC827-OR cell lines [HCC827OR_WES]

Project description:To investigate if there are new genetic mutations occurred within the HCC827 osimertinib resistant cells compared with the parental cells.

2024-03-13 | GSE223007 | GEO

Global transcriptional profiling of HCC827 lung adenocarcinoma cells in response to EGFR inhibition

Project description:mRNA sequencing of EGFR mutant HCC827 lung adenocarcinoma cells were treated with erlotinib (EGFR inhibitor) for 24hr to profile and characterize dysregulated pathways in response to EGFR inhibition

2021-06-24 | GSE178755 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of HCC827 and HCC827/GR cells Transcriptomes

Project description:HCC827 cells were obtained from American Type Culture Collection, and the gefitinib resistant HCC827/GR cells were established by gradient dose treatment for parental cells more than 6 months.Our study established an acquired gefitinib-resistant cell line, which exhibited epithelial-mesenchymal transition (EMT) and stem cell-like properties ann transcriptional sequencing and bioinformatics analysis confirmed that.

2022-04-14 | GSE199627 | GEO

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

Project description:The non-small cell lung cancer (NSCLC) cell line HCC827 harbors an activating EGFR mutation (exon 19 deletion) that confers sensitivity to the FDA-approved EGFR inhibitor erlotinib. By applying the ClonTracer barcoding system, we were able to show the presence of pre-existing sub-populations in HCC827 that contribute to erlotinib resistance. Prior studies implicated that MET amplification confers resistance to erlotinib in this cell line. Therefore we examined the effects of the c-Met inhibitor crizotinib on the barcoded HCC827 population when treated either sequentially or simultaneously with both inhibitors. Despite the significant reduction in barcode complexity, the erlotinib/crizotinib combination treatment failed to eradicate all of the resistant clones implying the presence of an erlotinib/crizotinib dual resistant subpopulation. We performed transcriptome profiling (RNA-seq) to elucidate the potential resistance mechanisms of the dual resistant subpopulation in comparison to vehicle-treated or single agent erlotinib-resistant HCC827 cell populations as controls. mRNA profiling of the subpopulations of human NSCLC cell line HCC827 that contribute to EGFR inhibitor erlotinib and MET inhibitor crizotinib resistance

2014-10-07 | E-GEOD-62118 | biostudies-arrayexpress

Defining the role of ZEB1 in the pathogenesis of lung cancer

Project description:Using an in vitro model for malignant transformation of human bronchial epithelial cells (HBECs) we have found epithelial-to-mesenchymal transition (EMT) and expression of the EMT-transcription factor ZEB1 are early and critical events. Specifically, we found preexisting oncogenic mutations in TP53 and KRAS were required for HBECs to engage EMT machinery in response to microenvironmental (serum/TGFβ) or specific oncogenetic (MYC) EMT-inducing factors, which induce EMT through distinct TGFβ-dependent and vitamin D receptor (VDR)-dependent pathways, respectively, with both requiring ZEB1. Functional studies demonstrated ZEB1 causally promotes the malignant progression of HBECs and tumorigenicity of NSCLC and small cell lung cancer (SCLC) lines. Mechanistically ZEB1 directly represses ESRP1 leading to increased mesenchymal splicing of CD44, which drives a switch to CD44hi status and defines a highly transformed subpopulation. This was supported by finding ZEB1 is expressed in early-stage primary non-small cell lung cancers (NSCLC), as early as stage IB tumors, and its expression correlates with TNM stage. We conclude that: ZEB1-induced EMT and associated ESRP1 and CD44 molecular changes are important biomarkers for lung cancer pathogenesis; TGFβ and VDR are EMT chemoprevention targets; and as such, ZEB1 represents an important therapeutic target in NSCLC and SCLC.

2016-08-31 | GSE77925 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data